Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 8Oxaliplatin 7Leucovorin 6Irinotecan 6Gemcitabine 5fludarabine 3aldesleukin 3Pemetrexed 3Nivolumab 3Cyclophosphamide 3Cetuximab 3Capecitabine 35,10-methylenetetrahydrofolic acid 3dehydroftorafur 2cobimetinib 2Specimen Handling 2Panitumumab 2Interleukin-2 2Docetaxel 2Bevacizumab 2130-nm albumin-bound paclitaxel 2tivozanib 1sodium propionate 1rucaparib 1rilotumumab 1repotrectinib 1regorafenib 1pralsetinib 1pertuzumab 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gastrointestinal Neoplasms × AMG 337 × Clear all
NCT02344810 2023-05-25

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Withdrawn
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡